Clinical Trial Results: Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial results for lebrolikizumab in adults and adolescents with moderate-to-severe atopic dermatitis show effectiveness and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Almirall, S.A. | Conditions: Atopic Dermatitis, Eczema | Phase 3 | Status: COMPLETED | Results posted: 2026-07-17